Aethlon medical announces publication of peer-reviewed journal article describing hemopurifier resin binding of seven covid-19 variants

San diego , july 28, 2022 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced the publication of a peer-reviewed journal article in plos one. the article, titled "removal of clinically relevant sars-cov-2 variants by an affinity resin containing galanthus nivalis agglutinin," contains data demonstrating that the proprietary gna affinity resin of the aethlon hemopurifier® efficiently captures seven clinically relevant variants of the sars-cov-2 virus responsible for the covid-19 pandemic.
AEMD Ratings Summary
AEMD Quant Ranking